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ABSTRACT 
The apparent rationale for the popular use of high doses of neuroleptics in psychotic pa-
tients is to increase the degree and speed of therapeutic response .However, several recent re-
ports have questioned these claims. The present study was undertaken with the aim to compare 
the efficacy of high and low oral doses of haloperidol in the treatment of acute and transient 
psychotic disorders. The sample comprised of forty patients of both sexes diagnosed as acute and 
transient psychotic disorder who were randomly assigned to high dose (20 mg/day) and low dose 
(5 mg /day) haloperidol groups with equal number of subjects (n=20) in both groups. Weekly 
assessment was done on Brief Psychiatric Rating Scale and Haloperidol Side-effects Check List 
(day 7, 14, 21, 28, 35 & 42). Both groups showed significant improvement in BPRS from baseline 
scores on all assessments. Comparison of.the improvement rate in both study groups revealed no 
significant difference. 
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Selection of the most appropriate dose 
of an antipsychotic agent may help to maximize 
clinical benefit and minimize neurological and 
other side effects (Baldessarini et al., 1988). 
The apparent rationale for the popular 
aggressive use of high potency agents in high 
doses is to increase the degree and speed of 
therapeutic response. However, there is good 
evidence that high doses of potent 
neuroleptics are not more beneficial or more 
rapidly effective than moderate doses (Ayd, 
1955). There is also some basis to suspect that 
high doses can yield inferior clinical effects as 
well as excessive neurological side effects 
(Wilkensand Malitz, 1960). 
Beckmann et al. (1990) have indicated 
that lower doses are adequate for most 
psychotic patients and that use of higher doses 
is not scientifically supported. Volavka et al. 
(1991) have suggested that there is an optimum 
range or therapeutic window for haloperidol. 
It is the acutely psychotic patients who 
have been subjected, in the past, to receive high 
doses of potent neuroleptics including haloperi-
dol for their treatment (Kinross-Wright, 1995; 
Danik & Goverdham, 1963; Mountain, 1963). 
Later, in the 1970's there were still more 
studies claiming success in applying high doses 
of potent neuroleptics for the treatment of 
acutely psychotic patients (Oldham & Batt, 
1971; Polack & Laycob, 1971; Sangiovanni et 
al., 1973; Donlon & Tupin, 1974; Carter, 1977; 
1978; Firling, 1978). However, recent reports 
have questioned the"se claims ( Bollini et al., 
1984; Baldessarini et al., 1988; Beckman & 
Laux1990; Volavka, 1992). 
The present work aims to compare the 
efficacy of high and low oral doses of 
haloperidol in the treatment of acute and 
transient psychotic disorders. 
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MATERIAL AND METHOD 
The sample for the study was selected 
from the patients of acute psychotic disorder of 
both sexes attending the Outpatients 
Department of Psychiatry, King George's 
Medical College, Lucknow, 
Subjects were diagnosed as per Interna-
tional Classification of Diseases-10 
criteria of Acute and transient psychotic 
disorders (F23). The sample for the study 
consisted of drug-naive patients fulfilling 
following selection criteria. 
Inclusion criteria was, age of the patients 
between 17 and 55 years (so as to minimise 
age induced variations). Exclusion criteria were, 
allergy or hypersentivity to haloperidol; 
severe medical illness - presence of any 
physical disorder requiring active medication 
especially renal, hepatic, cardio vascular and 
endocrinal diseases so as to reduce the chances 
of side effects, and drug levels could be kept 
more or less consistent; drug interaction could 
also be avoided; pregnancy - so as to minimise 
chances of teratogenicity; patients having 
neuropsychiatry illness e.g. epilepsy were 
excluded to maintain the homogeneity of the 
sample; mental retardation;drug induced 
psychosis or drug dependence;bipolar disorder; 
schizophrenia and other psychotic disorders; 
any other psychiatric illness; history of 
receiving antipsychotic medication during the 
present episode. 
The patients fulfilling the criteria of acute 
and transient psychotic disorder and selection 
criteria were included in the study.lnformed 
consent was obtained from each patients' 
relatives. All patients were assigned to a 6 week 
protocol. They were administered semi-struc-
tured proforma, Brief Psychiatric Rating Scale 
(B.P.R.S.) and Haloperidol Side-effects Check 
List on day 0 for baseline assessment. Patients 
were then randomly assigned either to high 
(20mg/day) dose or low (5mg/day) dose of oral 
haloperidol administered in identical capsules 
at bed time. They were given oral 
trihexyphenidyl 6mg/day in divided doses and 
lorazepam orally upto 6mg/day, if required, 
which was duly recorded in each case. 
Each patient was then evaluated on day 
7, 14, 21, 28, 35 and 42 using the B.P.R.S.and 
Haloperidol.Side-effects Check List. 
Patients were excluded from the study 
during administration of protocol for the follow-
ing reasons: 
1. Worsening of the patient's condition so as 
to require alternative medication. 
2. Withdrawal of consent to participate 
further in the trial. 
3. Absconding from the hospital or leaving 
against medical advise. 
4. Development of hypersensitivity or 
emergence of severeside-effects. 
5. Development of an acute physical 
illness requiring immediate intervention. 
Statistical analysis was carried out by 
paired't' test. 
RESULTS 
47 patients were initially included in the 
study and were divided into high dose group 
(n=22) and low dose groups (n=25) by random 
allocation. 7 patients were dropped-out prior to 
completion of protocol (high dose group =2 & 
low dose group = 5) due to following reasons: 
1. Withdrawal of consent -2 patients (1 patient 
from high dose group and 1 patient from low 
dose group). 
2. Had to be given parenteral medication -3 
patients due to excitement and refusal to 
take oral medication (all from low dose 
group). 
3. Patient absconded during the protocol -1 
patient (from low dose group). 
4. Patient developed severe side effects 
namely rigidity, tremor and akathisia -1 
patient (from high dose group). 
Thus 40 patients finally completed the 
study (high-dose group=20 and low-dose APURV KHANNA et al. 
group=20). 
The largest number of the subjects in the 
high dose (9, 45%) and low dose groups.(10, 
50%) were in the 21-30 yrs age group. Males 
constituted 60% of high dose group, while the 
low dose had an equal representation of both 
the sexes. Majority of the subjects were 
married and educated upto high school. 
Table 1 shows the clinical variables of 
the subjects. Duration of illness was upto 7 days 
in majority of the subjects. Most of the subjects 
had first episode and without any precipitating 
factor. Family history of psychosis was absent 
in most of the cases. 
TABLE 1 
CLINICAL VARIABLES 
DURATION OF ILLNESS 
(in days) 
Upto 7 
8-15 
16-30 
EPISODE 
First 
Second 
Third 
PRECIPITITATING 
FACTORS 
Present 
Absent 
FAMILY HISTORY 
OF PSYCHOSIS 
Present 
Absent 
High dose 
No. % 
7 
6 
7 
15 
4 
1 
1 
19 
3 
17 
35 
30 
35 
75 
20 
5 
5 
95 
15 
85 
Low dose 
No. % 
9 45 
5 25 
6 30 
14 70 
4 20 
2 10 
2 10 
18 90 
1 5 
19 95 
Table 2 shows the representation of 
subjects in diagnostic subcategories of acute 
and transient psychotic disorder according to 
ICD-10. 
TABLE 2 
DIAGNOSTIC CATEGORIES ACCORDING TO ICD -X 
F23.0 Acute polymorphic 
psychotic disorder without 
symptoms of schizophrenia 
F23.2 Acute schizophrenia 
like psychotic disorder 
F23.8 Other acute and 
transient psychotic disorders 
High dose 
No. % 
1 5 
12 60 
7 35 
Low Dose 
No. % 
10 50 
10 50 
TABLE 3 
COMPARISON OF CHANGE IN B.P.R.S. SCORE IN 
HIGH AND LOW DOSE GROUPS FROM BASELINE 
SCORES 
Baseline Score 
Day 7 
Day 14 
Day 21 
Day 28 
Day 35 
Day 42 
High Dose (n=20) 
MEAN+S.D. T 
26.95+6.3 
13.55+5.61 10.80* 
30+6.47 12.99* 
22.70+8.04 12.63* 
24.30+7.57 14.36* 
25.30+7.19 15.74* 
25.65+7.09 16.18* 
Low Dose(n=20) 
MEAN+S.D. T 
24.55+3.85 -
12.35+3.57 15.47* 
17.70+4.26 18.58* 
20.40+3.98 22.92* 
22.10+4.04 24.46* 
22.55+4.12 24.47* 
22.90+3.97 25.80* 
For all values d.f. = 19, *- p<001 
Table 3 shows the comparison of change 
in B.P.R.S. scores from baseline scores in high 
and low dose group (change in B.P.R.S score 
at day x = Baseline score - B.P.R.S. score at 
day x). 
The mean value of B.P.R.S. scores, 
using the paired t test were found to be highly 
significant at all stages of the study, starting from 
day 7 to day 42 when compared with the 
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baseline scores. 
At day 14, 2 subjects (10%) in each 
group showed psychotic symptoms. From day 
21 onwards no subject exhibited psychotic 
symptoms but had scores on other item of 
B.P.R.S. 
TABLE 4 
COMPARISON OF CHANGES IN B.P.R.S. SCORES 
BETWEEN HIGH AND LOW DOSE GROUPS 
Baseline Score 
Day 7 
Day 14 
Day 21 
Day 28 
Day 35 
Day 42 
High Dose (n=20) 
MEAN+S.D. 
24.55+3.85 
12.35+3.57 
17.70+4.26 
20.40+3.98 
22.10+4.04 
22.55+4.12 
22.90+3.97 
Low Dose( 
MEAN+S.D 
26.95+6.83 
13.55+5.61 
18.80+6.47 
2270+8.04 
24.30+7.57 
25.30+7.19 
25.65+7.09 
n=20) 
'f 
-
10.81 
0.64 
1.15 
1.15 
1.48 
1.51 
For all t comparisons d.f.=38, all t values are not significant 
Table 4 shows the inter-group 
comparison of mean changes in B.P.R.S. scores 
between the high and low dose groups. The 
difference in scores in the two groups was not 
found to be significant at any stage of 
evaluation. 
At day 0, lorazepam was required in 11 
(55%) subjects in high dose group while it was 
required in 14 (70%) subjects in low dose group 
(p=NS), while at day 7, it was required in 11 
(55%) subjects in high dose group and in 13 
(65%) subjects in low dose group (p=NS). 
At day 14, lorazepam was given to 11 
(55%) subjects in high dose group and 12 (60%) 
subjects in low dose group (p=NS). On day 21, 
lorazepam was used in 11 (55%) subjects in high 
dose group and 6 (30%) subjects in low dose 
group (p=NS). On day 28, 4 (20%) subjects in 
high dose group and 3 (15%) subjects in low 
dose group required it (p=NS). 
On day 35, 2 (10%) subjects in the high 
dose group and 3 (15%) subjects in the low dose 
group required it (p=NS). 
On day 42,1 (5%) subject in the high dose 
group and 3 (15%) subjects in the low dose 
group required lorazepam (p=NS). 
The commonest side effects in the high 
dose group were those of dry mouth-7 subjects 
(35%), and blurred vision-4 subjects (20%) on 
day 7 and of dry mouth -5 subjects (25%) and 
decreased motor activity -3 subjects (15%) on 
day 42. 
The commonest side efffects in the low 
dose group were those of dry mouth-3 subjects 
(15%), blurred vision -2 subjects (19%) and 
constipation -2 subjects (10%) on day 7. On day 
42 the commonest side effects in this group 
were those of constipation -3 subjects (15%) 
and blurred vision -2 subjects (10%). 
DISCUSSION 
The use of antipsychotics in lower doses 
is today an accepted practice. While just a few 
years ago, research in this area concentrated 
mainly on using high doses of antipsychotic 
drugs to abort psychosis i.e. rapid 
neuroleptization (Mountain, 1963; Polak & 
Laycob, 1971), today most studies are 
concentrating on using the minimum effective 
dose of neuroleptics (Volavaka, 1992). 
While most drug trials on acute psycho-
sis have been limited to time periods ranging 
from one hour (Gerstenzang and KrulisKy, 1977) 
to two hours (Man & Chen, 1973; Reschke, 
1974) or two days (Fitzgerald, 1969; Slotnick, 
1971; Ritter et al., 1972), very few have fol-
lowed-up the patient over a period (Levenson, 
1976; Erickson, 1978). Thus the 6 weeks dura-
tion of this study allowed for a more prolonged 
and complete evaluation of the subjects. 
A review of previous studies reveals high 
improvement rates on evaluation of subjects 
on a standard psychiatric rating scale in the low 
dose group. Fitzgerald (1969) reported 
improvement rate of 57% in the low dose group 
on evaluation of subjects after 2 days of 
administration of haloperidol. Ritter etal. (1972) 
reported improvement rate of 60% in the low 
dose group on evaluation after 2 days while 
Slotnick (1971) reported an improvement rate 
of 50% after 2 days in the low dose group. Man 
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6 Chen (1973) reported an improvement rate 
of 23% in the low dose group at 2 hours while 
Anderson et al. (1976) reported an improvement 
rate of 50% in the low dose group at 3 hours. 
Levenson et al. (1976) reported an improve-
ment rate of 75% on evaluation after 21 days 
in the low dose group. Gerstenzang & Krulisky 
(1977) in an evaluation of subjects after one 
hour reported an improvement rate of 50%. 
Erickson et al. (1978) evaluated patients in the 
variable dose group at time intervals of 1 day, 
5 days and 18 days and reported improvement 
rates of 26%, 60% and 69% respectively. 
Neborsky et al. (1981) evaluated subjects at 4 
hours, 14 hours and 7 days and reported 
improvement rates of 34%, 39% and 66% 
respectively. 
Other workers such as Escobar & Barron 
(1983), Dubin et al. (1985), Nishikawa (1985), 
Neto et al. (1988), Coryell & Kelly (1990), 
Volavka (1992) have all reported significant 
improvement rates of 68%, 71%, 79%, 74%, 
59% and 70 % respectively on evaluation after 
7 days. 
The findings of the present study are in 
consonance with the earlier studies. The base-
line values of B.P.R.S scores in the low dose 
group was 26.95+6.83.The group showed highly 
significant (p<.001) improvement on day 7 with 
mean change of 13.55+5.61, thus showing 
improvement of 50.12%- from baseline. The 
entire group then showed continuous 
improvement at all the following evaluations and 
no subjects showed a rising value of B.P.R.S. 
scores. 
In the high dose group Fitzgerald (1969) 
reported an improvement rate of 48% on 
evaluation after 2 days. Slotnick (1971) also 
evaluated patients after 2 days and reported 
an improvement of 50%. Ritter et al. (1972) 
reported an improvement of 68% in the high 
dose group on evaluation after 2 day, while Man 
6 Chen (1973) evaluated subjects after2 hours 
and reported improvement of 22%. Anderson 
et al. (1976) also evaluated patients after a short 
duration of 3 hours and reported improvement 
rate of 42%. Levenson et al. (1976) evaluated 
subjects after a longer duration of 21 days and 
reported an improvement of 80%. Gerstenzang 
& Krulisky (1977) on evaluation of subjects af-
ter 1 hour, reported an improvement of 77% 
while Erickson et al. (1978) on evaluation of 
subjects on days 1, 5.and 18 reported improve-
ment rates of 36%, 59% and 73% respectively. 
Neborsky et al. (1981) evaluated subjects after 
4 hours, 14 hours and 7 days and reported 
improvement rates of 40%, 38% and 65% 
respectively. 
Escobar & Barron (1983), Dubin et al. 
(1985), Nishikawa & Tsudo (1985), Neto et al. 
(1988), Coryell & Kelly (1990) and Volavka 
(1992) have also reported significant 
improvement rates of 65%, 73%, 70%, 55% and 
67% respectively after 7 days in the high dose 
group. 
In the present study too, patients in the 
high dose group showed highly significant 
improvement (p<.001) from the baseline at all 
the evaluations. The change in B.P.R.S. scores 
from the baseline at days 7,14, 21, 28, 35 and 
42 were 12.35+3.57 (50.30%), 17.70+4.26 
(72.09%), 20.40+3.98 (84.00%), 22.10+4.04 
(90.02%), 22.55+4.12 (91.85%) and 22.90+3.97 
(93.28%) respectively. 
The comparison of the subjects in the two 
groups of low and high dose of haloperidol also 
revealed findings similar to previous studies. 
These studies reported similar improvement 
rates in the two dosage groups with no signifi-
cant difference between them, namely, 
Fitzgerald (1969) 57% and 48% in the low and 
high dosage groups, Slotnick (1971) 50% and 
50%, Ritter et al. (1972) 60% and 68%, Man & 
Chen (1973) 23% and 22%, Anderson et al. 
(1976) 50% and 77%, Erickson et al. (1978) 26% 
and 36% on day 1, 60% and 59% on day 5 and 
69% and 73% on day 18 and Neborsky et al. 
(1981) 39% and 40% after 4 hours, 34% and 
38% after 14 hours and 66% and 65% after 7 
days. 
Escobar & Barron (1983), Dubin (1985), 
Nishikawa & Tsudo (1985), Neto et al. (1988), 
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Coryell and Kelly (1990) and Volavka (1992) 
have also reported similar improvement rates 
of 68% and 65%, 71% and 73%, 79% and 76%, 
74% and 70%, 59% and 55%, 70% and 67% 
respectively in the low and high dose groups 
after 7 days. 
From the findings of the present study, it 
can be concluded that the low dose of oral 
haloperidol is equally effective as high dose and 
causes lesser side effects. 
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